{"id":50076,"date":"2022-10-26T08:02:00","date_gmt":"2022-10-26T06:02:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/"},"modified":"2022-10-26T08:02:00","modified_gmt":"2022-10-26T06:02:00","slug":"merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/","title":{"rendered":"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Company\u2019s scientific leadership will be highlighted in 39 abstracts presented across its multiple sclerosis (MS) portfolio<\/b>\n<\/li>\n<li>\n<b>Data on investigational BTK inhibitor evobrutinib demonstrate long-term disease stability in people living with relapsing MS (RMS)<\/b>\n<\/li>\n<li>\n<b>Phase IV study highlights improvement in measures of Quality of Life in people living with RMS after two years of treatment with MAVENCLAD<sup>\u00ae<\/sup> (cladribine tablets)<\/b>\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">Not intended for UK and U.S. based media<\/span><\/b>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/4\/Asset_5%402x.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/21\/Asset_5%402x.jpg\"><\/a><\/p>\n<p>DARMSTADT, Germany&#8211;(BUSINESS WIRE)&#8211;Merck, a leading science and technology company, today announced it will present 39 abstracts at the 38<sup>th<\/sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held October 26-28, 2022 in Amsterdam, the Netherlands. The breadth of data highlights the Company\u2019s scientific leadership in multiple sclerosis (MS) and includes a presentation on a clinical trial with long-term data on Expanded Disability Status Scale (EDSS) scores in people with relapsing MS (RMS) treated with evobrutinib, an investigational agent, as well as new data demonstrating MAVENCLAD<sup>\u00ae<\/sup> (cladribine tablets) improved Quality of Life (QoL) in people with highly active RMS over two years. Additionally, a two-year follow-up study showed the onset of action on the reduction of MRI lesions with MAVENCLAD being maintained from Month 2 through two years.\n<\/p>\n<p>\n\u201cMultiple sclerosis has a profound impact on quality of life and improving this through therapy is often the most important outcome for people living with MS,\u201d said Gavin Giovannoni, Professor of Neurology, Queen Mary University of London. \u201cThe data presented at ECTRIMS further substantiate the therapeutic benefit of MAVENCLAD by improving Quality of Life measures over two years, combined with new evidence that the early effect on MRI lesions is maintained over that period.\u201d\n<\/p>\n<p>\nIn the final analysis of the open-label, single-arm, multicenter, Phase IV CLARIFY-MS study, statistically significant (p\u22640.0001) improvements from baseline were observed for Multiple Sclerosis Quality of Life-54 (MSQoL-54) physical and mental health composite scores (mean changes of 4.86 and 4.80, respectively; p&lt;0.0001). Changes in MSQoL-54 composite scores were consistent across treatment na\u00efve and prior disease-modifying treatment (DMT) subgroups. Annualized relapse rate was 0.13 in all patients (0.08 in patients who had not received DMT prior to receiving MAVENCLAD) and median EDSS was unchanged over two years. No new safety concerns emerged.\n<\/p>\n<p>\nAlso to be presented are new MRI outcomes data from the Phase IV MAGNIFY-MS study, which demonstrated an onset of action from Month 2 with sustained reduction in MRI lesion counts maintained out to two years in people with highly active RMS treated with MAVENCLAD. The proportion of lesion-free patients increased from 47% at baseline to 86.2% at the end of the study (Month 18\u201324). In the study, MRI lesions at baseline were compared over multiple time periods, from initial screening to Month 24. Over the two years, the benefit:risk profile of MAVENCLAD remained unchanged and in line with observations made during the clinical trial program.\n<\/p>\n<p>\nAdditionally, updated post-approval safety data will be presented based on an analysis of 56,300 patients who received MAVENCLAD post-approval, representing 95,664 patient-years of experience, as of July 2022. The study found the safety profile of MAVENCLAD is consistent with findings from the clinical development program and the CLARIFY-MS and MAGNIFY-MS studies.\n<\/p>\n<p>\n\u201cThe breadth of our data at ECTRIMS exemplifies our commitment to pushing forward scientific innovation with the development of evobrutinib, while generating new, meaningful data to demonstrate the safety profile and effectiveness of MAVENCLAD,\u201d said Jan Klatt, Senior Vice President, Head of Development Unit Neurology &amp; Immunology at Merck. \u201cOur goal is to ensure people living with MS, and those who treat them, have the information they need to manage their MS today and in the future.\u201d\n<\/p>\n<p>\nBeyond the MAVENCLAD and evobrutinib data presented, Merck will have several Company events, along with additional data from its MS portfolio at ECTRIMS 2022.\n<\/p>\n<p>\n<b>Company activities at ECTRIMS 2022:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n\u201cConnecting the dots: immune cells and CNS inflammation\u201d co-chaired by Professor Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Blizard Institute, Barts and the London School of Medicine and Dentistry, UK, and Celia Oreja-Guevara, MD, PhD, Hospital Cl\u00ednico San Carlos, Madrid, Spain (October 26, 2022, 13:15-14:15 CEST)\n<\/li>\n<li>\n\u201cNew tools for new challenges in multiple sclerosis\u201d chaired by Stephen Krieger, MD, Mount Sinai Hospital, New York, NY, USA (October 28, 2022, 14:15-15:15 CEST)\n<\/li>\n<li>\nProduct Theater: Early Experience with MAVENCLAD by Ravi Dukkipati, MD, WellSpan Neurology, York, PA, USA\n<\/li>\n<\/ul>\n<p>\nTo keep up to date with our activities at ECTRIMS along with future data and information, visit merckneurology.com\/newsroom or follow us on Twitter <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerckHealthcare&amp;esheet=52951610&amp;newsitemid=20221025005205&amp;lan=en-US&amp;anchor=%40MerckHealthcare&amp;index=1&amp;md5=ac4d427e0569a1c4e8997dc551332366\" rel=\"nofollow noopener\" shape=\"rect\">@MerckHealthcare<\/a> and LinkedIn: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fhealthcarebusinessofmerck%2F&amp;esheet=52951610&amp;newsitemid=20221025005205&amp;lan=en-US&amp;anchor=Healthcare+Business+of+Merck&amp;index=2&amp;md5=7dbcf183d73932345d4fb45c6c581db5\" rel=\"nofollow noopener\" shape=\"rect\">Healthcare Business of Merck<\/a>\n<\/p>\n<p>\nBelow is the full list of Merck-related abstracts accepted for presentation at ECTRIMS 2022:\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Abstract Name<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Authors<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>ID<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Presentation Details<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>MAVENCLAD Poster Presentations<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImprovements in Quality of Life Over 2 Years in Patients Treated With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: Final Analysis of CLARIFY-MS\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSolari A, Montalban X, Lechner-Scott J, Piehl F, Brochet B, Langdon D, Hupperts R, Selmaj K, Havrdova EK, Patti F, Brieva L, Maida EM, Alexandri N, Smyk A, Nolting A, Keller B, on behalf of the CLARIFY Investigators\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP108\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Jeannette Lechner-Scott\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEarly Onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDe Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X, Prat A, Schmierer K, Sellebjerg F, Vermersch P, Wiendl H, Keller B, Smyk A, Gardner L\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP717\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Nicola De Stefano\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUpdated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Liver Safety\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGiovannoni G, Leist T, Jack D, Galazka A, Nolting A\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP341\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Gavin Giovannoni\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHigh Adherence and Minimal Delays of Year 2 Treatment in People with Multiple Sclerosis Treated with Cladribine Tablets: Results from Multi-Country Patient Support Programmes\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOh J, Ayer M, Alroughani R, Lemieux C, Morgan K, D\u2019Eramo M, Vella T, Boshra A, de Souza S, Verdun di Cantogno E, Sabid\u00f3 M\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP727\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session:<\/b> 2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Jiwon Oh\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTreatment Emergent Adverse Events Experienced Early and Transiently in the Treatment Course with Cladribine Tablets: Data from the CLEVER Real-World Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nZiemssen T, Posevitz-Fejfar, Wagner T, \u00dcbler S, Richter J, M\u00fcller B, Penner I-K\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP772\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session:<\/b> 2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Talf Ziemssen\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMaven4: Phase IV Non-Interventional, Prospective, Spanish Multicenter Study to Evaluate Cladribine Tablets Long Term Effectiveness on Real-World Clinical Practice\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSaiz A, Aladro Benito Y, Costa-Frossard F, S\u00e1nchez Magro I, Rodr\u00edguez Antig\u00fcedad A\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP774\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Albert Saiz\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCladribine Protects SH-SY5Y Neuron-Like Cells from Oxidative Stress Conditions In Vitro\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEixarch H, Calvo-Barreiro L, Fissolo N, Boschert U, Comabella M, Montalban X, Espejo C\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP784\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Herena Eixarch\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nReal-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients With Multiple Sclerosis in England: The CLARENCE Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBrownlee W, Amin A, Herbert A, Ashton L\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP762\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Wallace Brownlee\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDecision-making Factors in Patient Choice to Initiate Treatment with Cladribine: A Preliminary Baseline Analysis From the STATURE Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAllan M, Grech L, Cartwright A, Harding J, Mardan J, O\u2019Maley J, Savickas S, Sharma M, Murambiwa P, Stockle P, Bardsley B, Butler E\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP304\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Michelle Allan\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAssessment of Treatment Satisfaction Across Oral DMTs for Multiple Sclerosis: a Preliminary Baseline Analysis from the STATURE Study.\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGrech L, Allan M, Cartwright A, Harding J, Mardan J, O\u2019Maley T, Savickas S, Sharma M, Murambiwa P, Stockle P, Bardsley B, Butler E\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1086\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nA Real-World Study of Four-Year Follow Up Study of Patients Treated with Oral Cladribine From 2018-2022\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nO\u2019Neill DTD, Sharma M, Dong G, Hodgkinson SJ\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1132\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nA Study of Activated and Na\u00efve T Regs and B Cell Subsets For 30 Months After the Use of Cladribine\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHodgkinson SJ, O\u2019Neill DTD, Sharma M, Dong G, Verma ND, Al-atiyah R, Hall BM\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP704\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Suzanna Hodgkinson\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCLADCOMS &#8211; CLADribine Tablets Long-Term Control of MS \u2013 a Post-Marketing Investigator Driven Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFink K, Nilsson P, Alonso L, Sveningsson A, Gunnarsson M, Lange N, Ayad A, Vrethem M, Burman J, Lycke J, Piehl F\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1060\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nClinical Effectiveness and Safety of Cladribine Tablets for Patients Treated at least 12 Months in the Swedish Post-Market Surveillance Study \u201cImmunomodulation and Multiple Sclerosis Epidemiology 10\u201d (IMSE 10)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRosengren V, Ekstr\u00f6m E, Forsberg L, Hillert J, Nilsson P, Dahle C, Svenningsson A, Lycke J, Landtblom A-M, Burman J, Martin C, Sundstr\u00f6m, Gunnarsson M, Piehl F, Olsson T\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP728\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Linda Forsberg\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSARS-CoV2 Exposure Rates and Serological Response of People Living With MS\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLonginetti E, Asplund K, Kockum I, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Mellerg\u00e5rd J, Frisell T, Olsson T, Piehl F\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP558\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Elisa Longinetti\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCOVID-19 Humoral and T-cell Mediated Vaccination Responses in People with Multiple Sclerosis\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVickaryous N, Rios F, Schalk L, Asardag AN, George K, Kang A, Baker D, Giovannoni G, Dobson R\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP781\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Nikki Vickaryous\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDifferences Between Clinical Trials and \u201cReal-World\u201d Use of Disease Modifying Therapies: Insights from the UK OPTIMISE:MS Pharmacovigilance Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDobson R, Matthews P, Miller A, Pindoria J, Waddingham E\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP763\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Ruth Dobson\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCladribine Treatment Exerts Specific Effects on Memory B Cell Immunoglobulin Repertoires in Multiple Sclerosis Patients\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRuschil C, Gabernet G, Kemmerer CL, Ziemann U, Nahnsen S, Kowarik MC\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1115\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Christoph Ruschil\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCladribine Effects on T and B Cell Subsets and T Cell Reactivity in Multiple Sclerosis\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHansen RH, von Essen MR, Mahler MR, Cobanovic S, Binko TS, Sellebjerg F\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP697\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Rikke Holm Hansen\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSafety and Efficacy of Cladribine Therapy Following a Treatment with Anti-CD20 Compounds in Relapsing Multiple Sclerosis Patients: A Pilot Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSacco R, Disanto G, Pravat\u00e0 E, Gobbi C, Zecca C\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1068\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Evobrutinib Poster Presentations<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEvobrutinib, a Bruton\u2019s Tyrosine Kinase Inhibitor, Maintains Lowered Serum Neurofilament Light Chain Levels Over 2.5 Years of Treatment, in Patients With Relapsing Multiple Sclerosis\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nKuhle J, Kappos L, Montalban X, Benkert P, Li Y, Thangavelu K, Hyvert Y, Tomic D\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1021\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Jens Kuhle\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMRI and Clinical Outcomes of Evobrutinib, a Bruton\u2019s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-label Extension to a Phase II Trial\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVermersch P, Arnold D, Wolinsky JS, Havrdova E, Kinkolykh A, Hyvert Y, Tomic D, Montalban X\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP731\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Patrick Vermersch\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEvobrutinib Exert a Therapeutic Action on EAE by Increasing the Peripheral and Central Classical Dendritic Cell Number and Maturation\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSerrano-Regal MP, Calahorra L, Alonso-Garc\u00eda I, Grenningloh R, Boschert U, Haselmayer P, Ortega MC, Mach\u00edn-D\u00edaz I, Camacho-Toledano C, Garc\u00eda-Arocha J, Clemente D\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP307\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Mari Paz Serrano-Regal\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEvobrutinib, a Bruton\u2019s Tyrosine Kinase Inhibitor, Acts on Microglia: Implications in the Treatment of Progressive Mechanisms in Multiple Sclerosis\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGeladaris A, Torke S, Grenningloh R, Boschert U, Br\u00fcck W, Weber MS\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP693\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Anastasia Geladaris\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nB cells infiltrating the MS brain: from local maturation to targeting by evobrutinib\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBogers L, van Langelaar J, Rijvers L, Engelenburg HJ, Melief M-J, Wierenga-Wolf AF, Rip J, Blok KM, de Vries HE, Hendriks RW, Boschert U, Smolders J, van Luijn MM\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP147\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Laurens Bogers\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImmune response following mRNA COVID-19 vaccination in patients with multiple sclerosis treated with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBar-Or A, Cross AH, Cunningham A, Hyvert Y, Seitzinger A, Drouin EE, Alexandri N, Tomic D, Montalban X\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP1188\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Amit Bar-Or\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Rebif<sup>\u00ae<\/sup> (interferon beta-1a) Subcutaneous Injection Poster Presentations<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nExploring the Relationship Between Serum GDF-15 and Disease Stability in Patients with a First Clinical Demyelinating Event Treated with Subcutaneous Interferon \u03b2-1a or Placebo in the REFLEX Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCoray M, Freedman MS, Barkhof F, Comi G, De Stefano N, Kappos L, Enz L, Seitzinger A, Jack D, Kuhle J, Mehling M\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1027\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Mali Coray\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEvolution of the RebiSmart\u00ae Autoinjector Device in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for Relapsing Multiple Sclerosis\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nArnaud L, Keiser M, Henninger E, Piras F, Seitzinger A, Jack D, Le Masne Q\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1079\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Dominic Jack\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nValidation of a Semi-Automated Method to Quantify Lesion Volume Changes in Multiple Sclerosis on 2D Proton Density- Weighted Images Using Subtraction Imaging\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMattiesing RM, Stel S, Mangroe AS, Brouwer I, Versteeg A, van Schijndel RA, Uitdehaag BMJ, Barkhof F, Vrenken H\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP634\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Rozemarijn M Mattiesing\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nExpression of peripheral blood IFN-inducible genes predicts treatment outcome in patients with secondary progressive multiple sclerosis treated with IFN-beta-1a\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGurevich M, Zilkha-Falb R, Menascu S, Magalashvili D, Dolev M, Sonis P, Mandel M, Achiron A\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP353\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Michael Gurevich\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Non-Product Specific Poster Presentations<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDISCOntinuation of disease-modifying therapies in MS (DISCOMS) Extension \u2013 Study Design and Baseline Demographics to Date\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEngebretson E, Cutter G, Fox R, Kister I, Miller A, Morgan C, Seale R, Corboy JR\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP1089\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nExpert Opinion on the Use of Contraception in People with Multiple Sclerosis\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHillert J, Bove R, Haddad L, Hellwig K, Houtchens M, Magyari M, Mercki G, Montgomery S, Nappi R, Stenager E, Thompson H, Tulek Z, Verdun di Cantogno E, Simoni M\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP080\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Jan Hillert\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSingle-Cell RNA Sequencing of Peripheral CD8+ T Cells of MS-Discordant Monozygotic Twins Reveals Disease-Associated Alterations In Immune Signaling\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nKavaka V, Mutschler L, Eglseer K, Flierl-Hecht A, K\u00fcmpfel T, Hohlfeld R, Kerschensteiner M, Gerdes L.A, Beltran E\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP159\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Vladyslav Kavaka\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCaregiver Burden and Associated Factors Among Caregivers of\n<\/p>\n<p class=\"bwcellpmargin\">\nPersons with Multiple Sclerosis: Application of a Specific Instrument\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVanotti S, Roman MS, Ferrandina F, Bauer J, Rosa R, Casas Parera I, Saladino ML, Caceres F\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEP0864\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>ePoster\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26-28, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Sandra Vannoti\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEvolutionarily Conserved Signatures of Microglia in Health and Disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSalinas V, Manouchehri N, Hussain R, Stuve O\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP131\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>1\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 26, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>16:30- 18:30 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Victor Salinas\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPeripheral Blood Immune Markers Associated With Immunosenescence in Multiple Sclerosis and Healthy Controls\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCarpentier Solorio Y, Daigneault A, Tastet O, Cl\u00e9net M-L, Farzam-kia N, Levert A, Da Cal S, Cl\u00e9ment W, Jamann H, Laurent C, Mamane VH, Ouedraogo O, Moratalla AC, Balthazard R, Lahav B, Prat A, Girard J-M, Duquette P, Rousseau M-C, Arbour N, Larochelle C\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP545\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter:<\/b> Catherine Larochelle\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nChemerin Correlates with MS Progression Parameters and Affects Intracellular Metabolism in Human Microglia and Macrophages\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLoonstra FC, van der Pol SM, Falize KF, van Heertum T, de Ruiter LR, Schoonheim MM, Killestein J, Uitdehaag BMJ, Kooij G, de Vries HE, Rijnsburger M\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP551\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Merel Rijnsburger\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAmyloid and some tau Proteinopathy are Observed in a Subset of Individuals with Multiple Sclerosis\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTaga M, Duquesne L, Lee A, Sigalov A, Peralta Cruz F, De Jager P\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nP1204\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>2\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>17:00- 19:00 CEST\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"4\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Non-Product Specific Oral Presentations<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBiological Roles of Myeloid Cell Subsets During CNS Inflammation\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nManouchehri N, Victor, Hussain RZ, Stuve O\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nO124\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Session: <\/b>Young Scientific Investigators&#8217; Session 3: Long-term outcomes and safety\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Date: <\/b>October 27, 2022\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Time: <\/b>15:00- 16:00 CEST\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presenter: <\/b>Navid Manouchehri\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About Evobrutinib<br \/>\n<br \/><\/b>Evobrutinib is an oral, highly selective CNS-penetrant inhibitor of Bruton\u2019s tyrosine kinase (BTK) in clinical development as a potential treatment for relapsing multiple sclerosis (RMS). It is the first BTK inhibitor to demonstrate clinical efficacy in the largest Phase II study with follow-up beyond three years as well as demonstrate an impact on early biomarkers of ongoing central inflammation that correlate with disease progression. Evobrutinib is designed to modulate B cell responses such as proliferation and antibody and cytokine release, as well as modulate macrophage\/microglia activation. It significantly reduced SEL volume and levels of blood NfL, markers of ongoing central inflammation and neurodegeneration that predict long-term disability. Evobrutinib was optimized for efficacy through the most comprehensive BTK inhibitor dose-finding study in RMS which demonstrated 75mg twice-daily dosing achieves maximal efficacy across endpoints by sustaining BTK inhibition throughout the dosing interval (&gt;95% BTK occupancy maintained in 98% of patients before next dose). It is currently under clinical investigation and is not approved for any use anywhere in the world.\n<\/p>\n<p>\n<b>About MAVENCLAD<sup>\u00ae<br \/>\n<br \/><\/sup><\/b>MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019, is the first and only short-course oral therapy for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis (MS), and MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS). Patients should follow healthcare provider instructions including cancer screening, contraception and blood tests. The approved dose of MAVENCLAD is 3.5 mg per kg body weight over two years, administered as one treatment course of 1.75 mg per kg per year, each consisting of two treatment weeks. The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes. MAVENCLAD causes a dose-dependent reduction in lymphocyte counts followed by recovery.\n<\/p>\n<p>\nBecause cladribine is cytotoxic, special handling and disposal instructions should be followed.\n<\/p>\n<p>\nMAVENCLAD has been approved in over 80 countries, including the European Union (EU), Canada, Australia and Switzerland, for various relapsing MS indications. Visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2427612-1%26h%3D1772676200%26u%3Dhttp%253A%252F%252Fwww.mavenclad.com%252F%26a%3Dwww.MAVENCLAD.com&amp;esheet=52951610&amp;newsitemid=20221025005205&amp;lan=en-US&amp;anchor=www.MAVENCLAD.com&amp;index=3&amp;md5=17542479d8ff802a77e9d7af22e42212\" rel=\"nofollow noopener\" shape=\"rect\">www.MAVENCLAD.com<\/a> for more information.\n<\/p>\n<p>\n<b>About Rebif<sup>\u00ae<br \/>\n<br \/><\/sup><\/b>Rebif (interferon beta-1a) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is used to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS.\n<\/p>\n<p>\n<b>About Multiple Sclerosis<br \/>\n<br \/><\/b>Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.\n<\/p>\n<p>\n<b>Merck in Neurology and Immunology<br \/>\n<br \/><\/b>Merck has a long-standing legacy in neurology and immunology, with significant R&amp;D and commercial experience in multiple sclerosis (MS). The company\u2019s current MS portfolio includes two products for the treatment of relapsing MS \u2013 Rebif<sup>\u00ae<\/sup> (interferon beta-1a) and MAVENCLAD<sup>\u00ae<\/sup> (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck\u2019s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).\n<\/p>\n<p>\nAll Merck press releases are distributed by e-mail at the same time they become available on the EMD Group website. Please go to <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merckgroup.com%2Fen%2Fcompany%2Fpress%2Fpress-release-subscription.html&amp;esheet=52951610&amp;newsitemid=20221025005205&amp;lan=en-US&amp;anchor=www.merckgroup.com%2Fsubscribe&amp;index=4&amp;md5=b8caf90f269283736654defc8e250e19\" rel=\"nofollow noopener\" shape=\"rect\">www.merckgroup.com\/subscribe<\/a> to register for your online, change your selection or discontinue this service.\n<\/p>\n<p>\n<b>About Merck<br \/>\n<br \/><\/b>Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 60,000 employees work to make a positive difference to millions of people\u2019s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices \u2013 the company is everywhere. In 2021, Merck generated sales of \u20ac 19.7 billion in 66 countries.\n<\/p>\n<p>\nScientific exploration and responsible entrepreneurship have been key to Merck\u2019s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x67;&#x65;&#111;ff&#x72;&#x65;&#x79;&#46;&#118;o&#x6b;&#x65;&#x73;&#64;&#109;e&#x72;&#x63;&#x6b;&#103;&#114;ou&#x70;&#x2e;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#103;e&#x6f;f&#x66;r&#x65;y&#x2e;&#118;&#x6f;&#107;&#x65;&#115;&#x40;&#109;e&#114;c&#x6b;g&#x72;o&#x75;&#112;&#x2e;&#99;&#x6f;&#109;<\/a><b><br \/><\/b>+31 (0)6 51 42 10 99\n<\/p>\n<p> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20221025005205\/en\/Merck-Showcases-Depth-of-MS-Portfolio-at-ECTRIMS-Supporting-Commitment-to-Advancing-MS-Care\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP392103_ypKzv-7ah0oHKWbnuHnevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZM7XiMhduiSeKMTNDLRqI_doMC3CVAuyHo5cJ7XfDuvA==\"> Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company\u2019s scientific leadership will be highlighted in 39 abstracts presented across its multiple sclerosis (MS) portfolio Data on investigational BTK inhibitor evobrutinib demonstrate long-term disease stability in people living with relapsing MS (RMS) Phase IV study highlights improvement in measures of Quality of Life in people living with RMS after two years of treatment with &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50076","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company\u2019s scientific leadership will be highlighted in 39 abstracts presented across its multiple sclerosis (MS) portfolio Data on investigational BTK inhibitor evobrutinib demonstrate long-term disease stability in people living with relapsing MS (RMS) Phase IV study highlights improvement in measures of Quality of Life in people living with RMS after two years of treatment with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-26T06:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/21\/Asset_5%402x.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care\",\"datePublished\":\"2022-10-26T06:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/\"},\"wordCount\":3454,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005205\\\/en\\\/1611708\\\/21\\\/Asset_5%402x.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/\",\"name\":\"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005205\\\/en\\\/1611708\\\/21\\\/Asset_5%402x.jpg\",\"datePublished\":\"2022-10-26T06:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005205\\\/en\\\/1611708\\\/21\\\/Asset_5%402x.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005205\\\/en\\\/1611708\\\/21\\\/Asset_5%402x.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/","og_locale":"en_US","og_type":"article","og_title":"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care - Pharma Trend","og_description":"Company\u2019s scientific leadership will be highlighted in 39 abstracts presented across its multiple sclerosis (MS) portfolio Data on investigational BTK inhibitor evobrutinib demonstrate long-term disease stability in people living with relapsing MS (RMS) Phase IV study highlights improvement in measures of Quality of Life in people living with RMS after two years of treatment with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-26T06:02:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/21\/Asset_5%402x.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care","datePublished":"2022-10-26T06:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/"},"wordCount":3454,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/21\/Asset_5%402x.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/","url":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/","name":"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/21\/Asset_5%402x.jpg","datePublished":"2022-10-26T06:02:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/21\/Asset_5%402x.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221025005205\/en\/1611708\/21\/Asset_5%402x.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/merck-showcases-depth-of-ms-portfolio-at-ectrims-supporting-commitment-to-advancing-ms-care\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50076"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50076\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}